Recursion Pharmaceuticals Reports Positive Phase 1b/2 TUPELO Trial Results, Validating AI-Driven Therapy for FAP [Yahoo! Finance]
Recursion Pharmaceuticals, Inc. - Class A (RXRX)
Company Research
Source: Yahoo! Finance
positive Phase 1b/2 results from its ongoing TUPELO trial evaluating REC-4881, which is a first-in-class allosteric MEK1/2 inhibitor for Familial Adenomatous Polyposis/FAP. FAP is a hereditary condition affecting over 50,000 people in the US and EU5, characterized by a near 100% lifetime risk of colorectal cancer due to APC gene mutations. The trial showed that REC-4881 achieved rapid clinical activity and significant durability of effect after treatment cessation. The findings suggested that REC-4881 not only shrinks existing polyps but may provide a sustained therapeutic benefit that halts the typically relentless progression of the disease. REC-4881 was discovered using the Recursion OS, which used AI-driven cellular phenomics to identify MEK1/2 inhibition as a rescue mechanism for APC loss-of-function. Originally evaluated by Takeda for solid tumors, the drug was in-licensed by Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) specifically for FAP based on these AI insights. The sa
Show less
Read more
Impact Snapshot
Event Time:
RXRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RXRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RXRX alerts
High impacting Recursion Pharmaceuticals, Inc. - Class A news events
Weekly update
A roundup of the hottest topics
RXRX
News
- JPMorgan Boosts Rating on Recursion Pharmaceuticals (RXRX) Amid AI-Driven Drug Pipeline [Yahoo! Finance]Yahoo! Finance
- Forget Recursion Pharmaceuticals Stock. This Is a Much Better Buy. [Yahoo! Finance]Yahoo! Finance
- Cathie Wood's ARK Investment Buys 755K Shares Of Recursion Pharmaceuticals, Inc. (RXRX) [Yahoo! Finance]Yahoo! Finance
- Recursion Pharmaceuticals Rises as Positive Phase 1b/2 Trial Results for REC-4881 Validate AI-Driven Drug Discovery Platform [Yahoo! Finance]Yahoo! Finance
- Cathie Wood Is Doubling Down on Recursion Pharmaceuticals Stock. Should You Buy RXRX Here? [Yahoo! Finance]Yahoo! Finance
RXRX
Earnings
- 11/5/25 - Beat
RXRX
Sec Filings
- 12/30/25 - Form 4
- 12/29/25 - Form 4
- 12/29/25 - Form 144
- RXRX's page on the SEC website